growth hormone secretagogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-22. Numbers and descriptions here follow the published literature rather than marketing material.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
== History == Cambrex was founded in 1979, when the Ennis Family acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. In 1990, Cambrex was listed on the NYSE. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco. Through multiple acquisitions during the late 1990s, the firm entered the bioscience and the chiral enzymatic catalyst markets. Cambrex acquired two contract biopharmaceutical manufacturing facilities in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, the firm decided to focus on its core competencies and sold the biologics business to Lonza Group. In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President. To broaden their biocatalysis platform, Cambrex acquired IEP in 2010, now known as Cambrex IEP. In 2019, Cambrex acquired Avista Pharma Solutions for $252m to become a fully integrated CDMO. In late 2019, Cambrex was acquired by an affiliate of the Permira funds. In 2020, Cambrex completed a major expansion at its Edinburgh, UK facility known for solid form screening alongside a biopharmaceutical expansion at its Durham, NC facility. Thomas Loewald was appointed CEO of Cambrex in September 2020. In 2022, Cambrex acquired Q1 Scientific, based out of Waterford, Ireland.
Croton lechleri is a species of flowering plant in the spurge family, Euphorbiaceae, that is native to northwestern South America. It is commonly known as sangre de grado (sic, Peruvian Spanish), sangre de drago (Ecuadorian Spanish) or sangre de grada (sic, Bolivian Spanish). They refer to this tree's (and several related species') thick red latex. The latex has medicinal properties, and is used by local peoples as a liquid bandage, applied to seal wounds, as it dries quickly to form a protective skin-like barrier. Its use by native people has led to scientific study and observation of its in vitro antioxidant activity as well as both mutagenic and antimutagenic behavior. The latex also contains a number of chemicals, including taspine. Oligomeric proanthocyanidins, another kind of chemical contained in the latex, have been investigated for the treatment of HIV-associated diarrhea under the name crofelemer. In January 2013, crofelemer, under the trade name Mytesi, was approved by the FDA for the treatment of non-infectious diarrhea in HIV+ patients.
== Early life == Jones was born in Cincinnati, Ohio on May 17, 1893, to an Irish father and Black American mother. Little is known about his mother who left his life when Jones was a child. His father, John Jones, was a railroad worker who struggled to raise him on his own. Jones was raised by a Catholic priest, Father Ryan, at a rectory in Cincinnati, Ohio, near Covington. Father Ryan took in Jones around the age of seven, and two years later, John Jones died. Jones left school at age 11 after the sixth grade. He went to nearby Cincinnati, Ohio, working odd jobs including a role as a garage cleaning boy. By age 14, Jones was working as an automobile mechanic and was later named garage foreman. Jones was largely self taught.
=== Processed tofu === Many forms of processed tofu exist. Some processing techniques probably originate before the days of refrigeration from the need to preserve tofu or to increase its shelf life. Other production techniques are employed to create tofus with different textures and flavors.
==== 1956–60 ==== In 1956, Sports Illustrated wrote that Mizell's return would help with St. Louis's pitching, a "major problem" for the Cardinals in 1955. His first outing back on April 17 was triumphant, as he allowed 12 hits but just two runs and came within one out of a complete game in a 4–2 victory over the Cincinnati Redlegs. From May 21 through June 9, he won five straight games, though he followed that up with three straight losses from June 15 through June 26. During the winning streak, in the second game of a May 27 doubleheader, he struck out 10 hitters in a 12–2 victory over the Chicago Cubs. In the first game of a doubleheader against Pittsburgh on August 23, he threw a four-hit shutout in a 3–0 victory. On September 7, 1956, facing the Redlegs, who were second to the Braves in a close pennant race, Mizell threw a two-hit shutout in a 1–0 victory. Six days later, he threw his second consecutive shutout, beating the Giants 5–0 and allowing just four hits. He had a 3.62 ERA for the Cardinals in 1956, and his 14–14 mark was reflective of St. Louis's .500 record. Mizell's 14 wins tied with Ron Kline and Hersh Freeman for 10th in the NL, but his 14 losses tied with Sam Jones, Al Worthington, and teammate Tom Poholsky for sixth. He ranked fifth in the NL with 153 strikeouts, and his mark of 6.6 strikeouts per nine innings pitched was good for third behind Jones's 8.4 and Harvey Haddix's 6.6. However, his 92 walks were third in the NL, behind Jones's 115 and Bob Buhl's 105.
Sources: en.wikipedia.org
sense A distinction made between the individual strands of a double-stranded DNA molecule in order to easily and specifically identify each strand. The two complementary strands are distinguished as sense and antisense or, equivalently, the coding strand and the template strand. It is the antisense/template strand which is actually used as the template for transcription; the sense/coding strand merely resembles the sequence of codons on the RNA transcript, which makes it possible to determine from the DNA sequence alone the expected amino acid sequence of any protein translated from the RNA transcript. Which strand is which is relative only to a particular RNA transcript and not to the entire DNA molecule; that is, either strand can function as the sense/coding or antisense/template strand.
where arg(x,y) is the clockwise angle between the X-axis and the vector (x,y); a function that is available in many programming languages as atan2(y,x). Conversely, given c and α, one can get the type (n,m) by the formulas:
However, package models do not solve the error threshold problem that originally motivated the idea of the hypercycle. A few years later, Maarten Boerlijst and Paulien Hogeweg, and later Nobuto Takeuchi, studied the replicator equations with the use of partial differential equations and cellular automata models, methods that already proved to be successful in other applications. They demonstrated that spatial self-structuring of the system completely solves the problem of global extinction for large systems and, partially, the problem of parasites. The latter was also analysed by Robert May, who noticed that an emergent rotating spiral wave pattern, which was observed during computational simulations performed on cellular automata, proved to be stable and able to survive the invasion of parasites if they appear at some distance from the wave core. Unfortunately, in this case, rotation decelerates as the number of hypercycle members increases, meaning that selection tends toward decreasing the amount of information stored in the hypercycle. Moreover, there is also a problem with adding new information into the system. In order to be preserved, the new information has to appear near to the core of the spiral wave. However, this would make the system vulnerable to parasites, and, as a consequence, the hypercycle would not be stable.
==== Size-exclusion chromatography (FPLC) ==== Due to the apparent size differences by the degree of PEGylation of the protein, size-exclusion chromatography (fast protein liquid chromatography or FPLC) can be used. There is a negative correlation between molecular weight and the retention time of the PEGylated protein in the chromatogram; larger protein, or more PEGylated protein elutes first, and smaller protein, or intact protein the latest.
Compensation prisoners then lose prospective job opportunities, face social marginalization, and lack access to resocialization programs, which ultimately facilitate reoffending. The research sheds light on how the mentally ill—and in this case, the poor—are further punished for certain circumstances that are beyond their control, and that this is a vicious cycle that repeats itself. Thus, prisons embody another state-provisioned mental hospital. Families of patients, advocates, and mental health professionals still call for an increase in more well-structured community facilities and treatment programs with a higher quality of long-term inpatient resources and care. With this more structured environment, the United States will continue with more access to mental health care and an increase in the overall treatment of the mentally ill. However, there is still a lack of studies on mental health conditions (MHCs) to raise awareness, knowledge development, and attitudes toward seeking medical treatment for MHCs in Bangladesh. People in rural areas often seek treatment from the traditional healers, and MHCs are sometimes considered a spiritual matter.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.